Celyad Announces Positive New Data from its CAR-T NKR-2 Phase I Trial at 2016 ASH Annual Meeting

Celyad Announces Positive New Data from its CAR-T NKR-2 Phase I Trial at 2016 ASH Annual Meeting

Celyad announces the approval to initiate its NKR-2 CAR-T Clinical Trial in Belgium

Celyad announces the approval to initiate its NKR-2 CAR-T Clinical Trial in Belgium

Celyad announces third quarter 2016 business update

Celyad announces third quarter 2016 business update

Celyad’s NKR-2 Phase I safety trial delivers encouraging results to be presented at ASH 2016

Celyad’s NKR-2 Phase I safety trial delivers encouraging results to be presented at ASH 2016

Celyad responds to misleading statements on its patent relating to allogeneic human primary T-Cells that are engineered to be TCR-deficient and express a CAR

Celyad responds to misleading statements on its patent relating to allogeneic human primary T-Cells that are engineered to be TCR-deficient and express a CAR

Celyad CEO to present at the 2016 Cell & Gene Meeting on the Mesa

Celyad CEO to present at the 2016 Cell & Gene Meeting on the Mesa

Celyad completes the NKR-2 Phase I trial with successful safety follow-up of the fourth dose level

Celyad completes the NKR-2 Phase I trial with successful safety follow-up of the fourth dose level

Celyad appoints Philippe Dechamps as General Counsel and Company Secretary

Celyad appoints Philippe Dechamps as General Counsel and Company Secretary

Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1): Clinical Trial Primary Outcomes

Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1): Clinical Trial Primary Outcomes

Celyad Reports First Half 2016 Financial Results and Operational Progress

Celyad Reports First Half 2016 Financial Results and Operational Progress

Celyad Letter to Shareholders

Celyad Letter to Shareholders

Celyad successfully completes safety follow-up of the first patient at the fourth dose level in the NKR-2 Phase I trial

Celyad successfully completes safety follow-up of the first patient at the fourth dose level in the NKR-2 Phase I trial